US stock surged | AstraZeneca (AZN.US) rises more than 4% in pre-market trading, Q3 core earnings per share exceed expectations

According to the Wise Finance APP, on Thursday, AstraZeneca (AZN.US) rose more than 4% before the market opened, reaching $84.92. AstraZeneca announced its third-quarter performance, with total revenue increasing by 12% year-on-year to $15.191 billion, core earnings per share at $2.38, higher than the market expectation of $2.27, benefiting from strong sales of cancer and diabetes drugs. Revenue for the first nine months increased by 10% year-on-year to $43.236 billion, with core earnings per share at $7.04. The company reiterated that annual revenue will achieve high single-digit growth and core earnings per share will achieve low double-digit growth, which is in line with market expectations. The company plans to announce an annual dividend of $3.20 per share in 2025, up from $3.10 last year.